Healthcare
Seegnal Reports Second Quarter 2026 Financial Results and Provides Business Update
Expanded Israeli Hospital Footprint with Five-Year Deployment at Nazareth Hospital EMMS Second Quarter Revenue Increased 15% to $351,000 and First Half Revenue Increased 16% to $706,000 CALGARY, Alberta, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) (“Seegnal” or the “Company”), a developer of innovative healthcare technology focused on mitigating medication risks, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update. R
About this update from Seegnal Inc.
Expanded Israeli Hospital Footprint with Five-Year Deployment at Nazareth Hospital EMMS Second Quarter Revenue Increased 15% to $351,000 and First Half Revenue Increased 16% to $706,000 CALGARY, Alberta, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a developer of innovative healthcare technology focused on mitigating medication risks, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update. Recent Business Highlights Financial Results for the Three and Six Months Ended June 30, 2026 All figures are in U.S. dollars unless otherwise noted. The following disclosure does not constitute full disclosure of the Company's financial and operational condition and is qualified by, and should be read in conjunction with, the Company's Management's Discussion and Analysis for the three and six months ended June 30, 2026 (the "MD&A") and corresponding financial statements, available under the Company's profile on SEDAR+ at www.sedarplus.ca . About Seegnal Seegnal Inc. (TSXV: SEGN) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company's SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age, and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing, and advance a more personalized standard of patient care. Seegnal's technology is deployed across healthcare settings and is used by more than 15,000 clinicians in daily practice. For additional Company information, please visit https://investors.seegnal.com/ and follow us on LinkedIn . Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements regarding the Company's revenue growth and commercial expansion; the adoption, deployment and integration of the Seegnal platform, including at Nazareth Hospital EMMS and other healthcare institutions; the Company's entry into and expansion within the U.S. healthcare market, including the conversion of its letter of intent and pilot program into commercial arrangements; the Company's ability to complete the Extended Offering; the completion, timing and terms of the Company's non-brokered private placement; the Company's liquidity, funding initiatives and ability to continue as a going concern; and management's expectations regarding future performance. Forward-looking information is based on assumptions and is subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to obtain financing on acceptable terms or at all, its history of losses and going concern, the early stage of its U.S. market entry, reliance on key customers and healthcare institutions, currency fluctuations, and the geopolitical situation in Israel. For a more complete discussion of the risks and uncertainties applicable to the Company, please refer to the risk factors described in the Company's most recently filed annual management's discussion and analysis, available under the Company's profile on SEDAR+ at www.sedarplus.ca . The forward-looking information in this news release is made as of the date hereof, and the Company undertakes no obligation to update it except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Company Contact: Seegnal Inc. Elad Bibi-Aviv, Chief Executive Officer +1 (929) 248 4652 Investor Relations Contact: Arx Investor Relations North American Equities Desk [email protected]